MedCity News April 10, 2023
The FDA has asked for more information about cardiac complications reported last year in a Phase 1 study for the Molecular Templates cancer drug, MT-0169. The partial clinical hold comes as the biotech works through a corporate restructuring as well as second Nasdaq de-listing notice.
A Molecular Therapeutics cancer drug candidate, one of the surviving programs of a recent corporate shakeup that slashed the company’s workforce in half, is now on pause. The FDA is asking for more information about two patients whose cardiac problems reported last year led to a dose reduction in the Phase 1 clinical trial.
The partial clinical hold announced late Friday means patients already in the study can continue to receive the experimental cancer treatment,...
Today's Sponsors
Today's Sponsor